For New Zealand Residents Only

Where can I find out more about asthma?

Answer five questions to see how well your asthma has been managed over the last four weeks.

It may be useful for you to discuss your test score with your doctor or nurse.
Take the test
See the latest Family Health Diary information on Breo
Visit page
More information and support for people with asthma is available from:
Visit page
Visit page

Download

Find out more about Asthma:

Any information provided on this website should be discussed with a health care professional (HCP) and does not replace a HCP's advice.

Clicking on the above links will lead you to a third-party website, and GSK is not responsible for the content of that website. By clicking on the Asthma Control Test link, you are leaving a GSK New Zealand website to a non-branded, international website developed by GSK.

References: 1. Breo Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz 2. Breo Ellipta Consumer Medical Information, GSK New Zealand, available at www.medsafe.govt.nz 3. PHARMAC Pharmaceutical Schedule February 2024 4. Woodcock A;Lancet;2017;390;2247-2255 5. O'Byrne PM, et al. EurRespir J 2014;43:773-782 6. Beasley R, et al. The New Zealand Medical Journal; 2020;133:1-38 7. Svedsater H, et al. NPJ Prim Care Respir Med 2014;24:14019. 8. Breo Ellipta Patient Information Leaflet, GSK New Zealand December 2023.

Breo Ellipta (fluticasone furoate/vilanterol trifenatate inhaler 100/25mcg per inhalation) is a Prescription Medicine. Breo Ellipta is used for the regular treatment of asthma (12 years of age and older) and for adults with Chronic Obstructive Pulmonary Disease (COPD). Breo Ellipta 100/25mcg is a fully funded medicine; Breo Ellipta 200/25mcg is an unfunded medicine (dose indicated in asthma only). Use strictly as directed. Breo Ellipta is not for relief of acute symptoms; a separate reliever inhaler may be required. Always carry your reliever inhaler. Do not discontinue Breo Ellipta without medical advice. Breo Ellipta has risks and benefits. Tell your doctor: If you are taking any other medicines or herbal remedies, you have liver disease, heart problems, high blood pressure, pulmonary tuberculosis (TB), infection of the lungs (pneumonia) or weak bones (osteoporosis). Side Effects: Headache, common cold, oral thrush, infection of the nose sinuses or throat, flu (influenza), pain and irritation at the back of the mouth and throat, inflammation of the sinuses, pneumonia and weakening of the bones, leading to risk of fractures. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. For more information see Breo Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor's charges apply. Ask your doctor if Breo Ellipta is right for you. Use strictly as directed.

Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Breo Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.

TAPS NP21174-PM-NZ-FFV-WCNT-200001 Date of Approval: 07 2024 Date of Expiry: 07 2026

Where can I find out more about asthma?

More information and support for people with asthma is available from:

Any information provided on this website should be discussed with a health care professional (HCP) and does not replace a HCP's advice.